GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Total Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹12,449 Cr | ₹11,173 Cr | ₹10,611 Cr | ₹8,778 Cr | ₹7,834 Cr |
What is the latest Total Liabilities ratio of GLAND PHARMA ?
| Year | Total Liabilities |
|---|---|
| Mar2026 | ₹12,449 Cr |
| Mar2025 | ₹11,173 Cr |
| Mar2024 | ₹10,611 Cr |
| Mar2023 | ₹8,778 Cr |
| Mar2022 | ₹7,834 Cr |
How is Total Liabilities of GLAND PHARMA Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹12,449 Cr | 11.42 | |
| Mar2025 | ₹11,173 Cr | 5.30 | |
| Mar2024 | ₹10,611 Cr | 20.89 | |
| Mar2023 | ₹8,778 Cr | 12.05 | |
| Mar2022 | ₹7,834 Cr | - | |
Compare Total Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹47,402.9 Cr | 1.9% | 12.9% | 49.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,994.0 Cr | -0% | -4.5% | 15.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹240,249.0 Cr | 5.9% | 16.1% | 49.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,135.0 Cr | 3% | 3% | 34% | Stock Analytics | |
| CIPLA | ₹114,708.0 Cr | -0.4% | -3.6% | -11.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,074.9 Cr | NA | 2.8% | -7.1% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 1.9% |
12.9% |
49.5% |
| SENSEX | -0.8% |
0.2% |
-6% |
You may also like the below Video Courses